World's Best Scientists 2026 revealed!
Anthony W. Tolcher

Anthony W. Tolcher

D-Index & Metrics

Medicine

D-Index
86
Citations
30874
World Ranking
14006
National Ranking
7107

Anthony W. Tolcher publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anthony W. Tolcher sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 699 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anthony W. Tolcher D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony W. Tolcher sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anthony W. Tolcher is affiliated with Texas Oncology in the United States. Their research contributions primarily lie within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. They have a significant focus on oncology and molecular biology with additional expertise covering radiology, nuclear medicine and imaging, immunology, and pulmonary and respiratory medicine.

Their work touches on several specialized subjects including cancer immunotherapy and biomarkers, monoclonal and polyclonal antibodies research, HER2/EGFR in cancer research, CAR-T cell therapy research, cancer research and treatments, peptidase inhibition and analysis, and colorectal cancer treatments and studies.

Frequent collaborators in their research include Alexander I. Spira, Erika Hamilton, Timothy A. Yap, Patricia LoRusso, and Melissa L. Johnson. The scholar has published extensively in respected venues, with notable recurrent publication outlets being:

  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Annals of Oncology

Representative recent papers authored or co-authored by Anthony W. Tolcher include:

  • Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial (2022), Journal for ImmunoTherapy of Cancer
  • First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01 (2023), Journal of Clinical Oncology
  • Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study (2024), Journal of Clinical Oncology
  • First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. (2022), Journal of Clinical Oncology
  • First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors (2021), Clinical Cancer Research

Best Publications

  • Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

    Mark E. Davis;Jonathan E Zuckerman;Chung Hang J Choi;David Seligson

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

    Timothy A. Yap;Li Yan;Amita Patnaik;Ivy Fearen

  • Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma

    Randy D. Gascoyne;Sheryle A. Adomat;Sheryle A. Adomat;Stanislaw Krajewski;Stanislaw Krajewski;Maryla Krajewska;Maryla Krajewska

  • Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer

    Toshio Shimizu;Anthony W. Tolcher;Kyriakos P. Papadopoulos;Muralidhar Beeram

  • Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

    Alain C. Mita;Louis J. Denis;Eric K. Rowinsky;Johann S. DeBono

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

    A W Tolcher;S L Gerson;L Denis;C Geyer

  • Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

    Monica M. Mita;Alain C. Mita;Quincy S. Chu;Eric K. Rowinsky

  • Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

    Anthony W. Tolcher;John Sarantopoulos;Amita Patnaik;Kyriakos Papadopoulos

  • Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

    Jonathan E. Zuckerman;Ismael Gritli;Anthony Tolcher;Jeremy D. Heidel

  • Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

    Anthony W. Tolcher;Steven Sugarman;Karen A. Gelmon;Roger Cohen

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

    Anthony W. Tolcher;Alain Mita;Lionel D. Lewis;Christopher R. Garrett

  • Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

    Anthony W. Tolcher;Leonel Ochoa;Lisa A. Hammond;Amita Patnaik

  • Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

    Anthony W. Tolcher;Wells A. Messersmith;Stanislaw M. Mikulski;Kyriakos P. Papadopoulos

  • Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

    Sant P. Chawla;Arthur P. Staddon;Laurence H. Baker;Scott M. Schuetze

  • A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

    Shahneen K. Sandhu;Kyri Papadopoulos;Peter C. Fong;Amita Patnaik

Frequent Co-Authors

Amita Patnaik
Amita Patnaik University of Chicago
Patricia LoRusso
Patricia LoRusso Yale University
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Keith T. Flaherty
Keith T. Flaherty Harvard University
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing a career in medicine opens a wide array of academic and professional options beyond traditional MD or DO routes. Today, online education has made it easier than ever for students and professionals to advance or specialize in various healthcare fields.

For registered nurses seeking an advanced practice role, rn to fnp bridge programs offer a streamlined pathway to become a Family Nurse Practitioner. Alternatively, those interested in growing demand within nutrition and wellness might explore best online nutrition programs to step into roles like dietitian or health coach.

Many healthcare professionals view management as a fulfilling next step. Accredited graduate degrees such as online mha programs can prepare you for leadership in hospitals and health systems. For RNs balancing work and education, accelerated rn to bsn online without clinicals options are available, allowing career advancement with maximum flexibility.

Exploring these online degrees expands your potential career pathways, empowering you to shape a future in healthcare that fits your interests and schedule.

Best Scientists Citing Anthony W. Tolcher

Trending Scientists

Recently Published Articles